Legal & General Group
APGE

Legal & General Group’s Apogee Therapeutics APGE Stock Holding History

Legal & General Group’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.34M Buy
32,695
+5,277
+19% +$475K ﹤0.01% 1655
2026
Q1 		$2.31M Sell
27,418
-5,438
-17% -$395K ﹤0.01% 1856
2025
Q4 		$2.48M Buy
32,856
+5,193
+19% +$327K ﹤0.01% 1890
2025
Q3 		$1.1M Sell
27,663
-26
-0.1% -$993 ﹤0.01% 2213
2025
Q2 		$1.2M Buy
27,689
+1,907
+7% +$72.5K ﹤0.01% 2176
2025
Q1 		$963K Sell
25,782
-91
-0.4% -$3.52K ﹤0.01% 2200
2024
Q4 		$1.17M Buy
25,873
+5,003
+24% +$255K ﹤0.01% 2181
2024
Q3 		$1.23M Sell
20,870
-218
-1% -$10.4K ﹤0.01% 2163
2024
Q2 		$830K Buy
21,088
+829
+4% +$40.2K ﹤0.01% 2254
2024
Q1 		$1.35M Buy
20,259
+9,922
+96% +$433K ﹤0.01% 2088
2023
Q4 		$289K Buy
10,337
+7,157
+225% +$143K ﹤0.01% 2637
2023
Q3 		$67.7K Buy
+3,180
New +$70.1K ﹤0.01% 2850

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Legal & General Group's APGE Position: Q2 2026 in Review

Legal & General Group increased its Apogee Therapeutics (APGE) stake by 19% in Q2 2026, buying an estimated $475K and bringing the position to 32,695 shares worth $4.34M. The position accounts for ﹤0.01% of the portfolio, ranked #1655.

Legal & General Group first reported a position in APGE in Q3 2023 and has held it in 12 quarters since. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Legal & General Group held 32,695 shares of Apogee Therapeutics worth $4.34M as of Q2 2026.
  • Legal & General Group bought 5,277 Apogee Therapeutics shares in Q2 2026, an estimated $475K.
  • Apogee Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #1655 holding.
  • Legal & General Group first reported a position in Apogee Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • 289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.